上海医药集团股份有限公司(02607)7月18日公告称,公司董事会已于2026年7月17日批准参与设立“上海上实生物医药产业私募基金合伙企业(有限合伙)(暂定名)”(下称“上海生物医药二期基金”)。该基金计划募集规模为人民币150亿元,首期各合伙人拟合计认缴150亿元,其中上海医药作为有限合伙人认缴3亿元,占比20.00%。
上海医药集团股份有限公司(02607)7月18日公告称,公司董事会已于2026年7月17日批准参与设立“上海上实生物医药产业私募基金合伙企业(有限合伙)(暂定名)”(下称“上海生物医药二期基金”)。该基金计划募集规模为人民币150亿元,首期各合伙人拟合计认缴150亿元,其中上海医药作为有限合伙人认缴3亿元,占比20.00%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.